BIOXCEL THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3460 USD | +0.06% |
|
-8.35% | -7.52% |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Pharmaceuticals | - | - | - | 375K | 1.38M | |||
Total Assets | 36.39M | 220M | 239M | 206M | 73.7M | |||
Interest Expense | - | -27K | -40K | -8.21M | -13.31M | |||
CAPEX | -870K | -316K | -445K | -139K | -20K | |||
EBT | -32.97M | -82.17M | -107M | -166M | -179M | |||
D&A | 156K | 188K | 297K | 327K | 318K | |||
Operating Income | -33.6M | -82.3M | -107M | -160M | -172M | |||
Net Income | -32.97M | -82.17M | -107M | -166M | -179M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
United States | - | - | - | 375K | 1.38M | |||
Total Assets | 36.39M | 220M | 239M | 206M | 73.7M | |||
Interest Expense | - | -27K | -40K | -8.21M | -13.31M | |||
D&A | 156K | 188K | 297K | 327K | 318K | |||
CAPEX | -870K | -316K | -445K | -139K | -20K | |||
Net Income | -32.97M | -82.17M | -107M | -166M | -179M | |||
EBT | -32.97M | -82.17M | -107M | -166M | -179M | |||
Operating Income | -33.6M | -82.3M | -107M | -160M | -172M |
- Stock Market
- Equities
- BTAI Stock
- Financials BioXcel Therapeutics, Inc.
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition